Monsanto s Spin on its Roundup herbicide is Unwinding

Similar documents
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center

Non-Hodgkin Lymphoma. Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract.

Lymphatic system component

Understanding your diagnosis. Dr Graham Collins Consultant Haemtologist Oxford University Hospitals

Lymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital

7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)

Overview of Cutaneous Lymphomas: Diagnosis and Staging. Lauren C. Pinter-Brown MD, FACP Health Sciences Professor of Medicine and Dermatology

Indolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital

Aggressive Lymphomas - Current. Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre

Large cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s

A Guide for Patients and Caregivers

Indolent Lymphomas: Current. Dr. Laurie Sehn

If searched for the ebook Guide mesothelioma in pdf form, then you have come on to the correct site. We furnish the complete version of this book in

Lymphoma and Myeloma Kris3ne Kra4s, M.D.

Lymphoma: The Basics. Dr. Douglas Stewart

Pathology #07. Hussein Al-Sa di. Dr. Sohaib Al-Khatib. Mature B-Cell Neoplasm. 0 P a g e

BENZENE LITIGATION: AN OVERVIEW JOHN TOMLINSON

LYMPHOMA DIAGNOSIS and PROGNOSIS. LC Lim Dept of Hematology Singapore General Hospital

Lymphoma: What You Need to Know

Update in Lymphoma Imaging

Neoplasms/Lymphoma/Leukemia

KING COUNTY SUPERIOR COURT, WASHINGTON STATE CAUSE NO SEA

Lymphoma (Lymphosarcoma) by Pamela A. Davol

7.342 Chronic infection and inflammation: What are the consequences on your health? Instructors Eva Frickel and Sara Gredmark

37 2 Blood and the Lymphatic System

Lymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC

Leukemia And Lymphoma In The Nervous System

Molecular Pathology of Lymphoma (Part 1) Rex K.H. Au-Yeung Department of Pathology, HKU

What is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias

Blood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen

Lymphoma is a cancer that develops in the white blood cells (lymphocytes) of the lymphatic system, which is part of the body's immune system.

Chronic Lymphocytic Leukemia (CLL)

LEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University

During past decades, because of the lack of knowledge


NON- HODGKIN LYMPHOMA

TAXOTERE: WHAT YOU NEED TO KNOW ABOUT IT

WHO Classification. B-cell chronic lymphocytic leukemia/small T-cell granular lymphocytic leukemia

Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint

Clinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages)

Lymphatic System Disorders

CLINICAL MEDICAL POLICY

Corporate Medical Policy

Pathology of Hematopoietic and Lymphoid tissue

155.2 Malignant neoplasm of liver not specified as primary or secondary. C22.9 Malignant neoplasm of liver, not specified as primary or secondary

Aggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017

Lymphoma Read with the experts

NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)

Hodgkin's Lymphoma. Symptoms. Types

Lymphoma accounts for 10-20% of all canine cancers and is by far the most common canine blood cancer.

HODGKIN LYMPHOMA DR. ALEJANDRA ZARATE OSORNO HOSPITAL ESPAÑOL DE MEXICO

WHAT ARE PAEDIATRIC CANCERS

88-year-old Female with Lymphadenopathy. Faizi Ali, MD

Rituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous)

CLINICAL MEDICATION POLICY

Retroperitoneal lymphoma mixed cell type icd 10

A 64yo female with tuberculous empyema not improving on treatment: A tribute and farewell to Dr. Alphonse Kayembe

CLINICAL MEDICATION POLICY

Pathology of Hematopoietic and Lymphoid tissue

HIV and AIDS Related Cancers DR GORDON AMBAYO UHS

Understanding Lymphoma

Non-Hodgkin lymphoma

CLINICAL MEDICAL POLICY

Rituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's Lymphoma

A CASE OF PRIMARY THYROID LYMPHOMA. Prof Dr.Dilek Gogas Yavuz Marmara University School of Medicine Endocrinology and Metabolism Istanbul, Turkey

Talcum Powder Fact Sheet

Clinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: PA.CP.PHAR.307

Imbruvica. Imbruvica (ibrutinib) Description

Lymphoma in Dogs What You Need to Know

Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

GAZYVA: for follicular lymphoma that has not responded to or has returned after treatment

Contents. vii. Preface... Acknowledgments... v xiii

Small B-cell (Histologically Low Grade) Lymphoma

LYMPHOMAS an overview of some subtypes of NHLs

Lymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University

Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies

TRACKING CASE NEWS AND DEVELOPMENTS IN BENZENE AND RELATED LITIGATION. Leap of Faith: Introduction

Involvement of Abdominal and Pelvic Lymph Nodes in Non--Hodgkin Lymphoma: the Nodal Distribution in Chinese Patients

B. Misunderstanding about clinical trials as an effective option to treatment; and

What is Thyroid Cancer? Here are four types of thyroid cancer:

ACHIEVING EXCELLENCE IN ABSTRACTING: LYMPHOMA

Watch and Wait. A Guide for Patients

Roche s subcutaneous formulation of MabThera approved in Switzerland for the treatment of common types of non-hodgkin lymphoma

PET-imaging: when can it be used to direct lymphoma treatment?

Aggressive B-Cell Lymphomas

The Lymphomas. An overview..

PhenoPath. Diagnoses you can count on B CELL NON-HODGKIN LYMPHOMA

Investor Update. Downloads. Services PDF. Basel, 23 June 2017

Surviving Leukemia And Hodgkin's Lymphoma: An Overview Of Effective Treatment Methods By Melinda Baxter

Featured Topic: Cold and Flu (4 slides)

Relapsed acute lymphoblastic leukemia. Lymphoma Tumor Board. July 21, 2017

Michi Shinohara MD Associate Professor University of Washington/Seattle Cancer Care Alliance Dermatology, Dermatopathology

* MILIARY MOTTLING --

Immune System.notebook March 07, Maintaining Dynamic Equilibrium. Immune system 1st, 2nd and 3rd line of defense Immune disorders

REPORT ON PROSPECTIVE AUDIT OF LYMPHOMA PATIENTS BORDERS, FIFE, AND LOTHIAN DIAGNOSED IN 2008

Burkitt lymphoma. Sporadic Endemic in Africa associated with EBV Translocations involving MYC gene on chromosome 8

FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers

Transcription:

Monsanto s Spin on its Roundup herbicide is Unwinding By: Thomas T. Dunbar, Esq. Recently, information about the potential danger posed by Monsanto s Roundup has surfaced as a result of information discovered in lawsuits against Monsanto s Roundup weed killer. Research suggests that exposure to the active ingredient in Roundup, glyphosate, may double the overall risk of Non-Hodgkin s Lymphoma ( NHL ) and triple the risk of B-cell lymphomas. Non-Hodgkin s lymphoma is a term used to describe a group of similar cancers which attack the lymphatic system. It is also known as NHL or non-hodgkins disease and can include a number of different sub-types of lymphoma with varying degrees of aggressiveness. While there are a number of potential causes, some cases of non-hodgkin s lymphoma diagnosed in recent years may have been caused by side effects of Roundup exposure. Roundup is a popular weed killer and herbicide that the World Health Organization identified as a potential human carcinogen in 2015. Although it appears that Monsanto knew or should have known about the link between Roundup and NHL, the manufacturer failed to provide adequate warnings about the potential lymphoma risk. Dunbar Law Office, P.C. is reviewing potential non-hodgkins lymphoma lawsuits against Monsanto for farm workers, landscapers and others exposed to large amounts of the weed killer. To review a potential case for yourself or a loved one, request a free consultation and claim evaluation. 1

Roundup Non-Hodgkins Lymphoma (NHL) Risk Monsanto s Roundup is the most widely used weed killer in the United States, with an estimated 283 million pounds per year sprayed throughout the United States. The product contains the herbicide glyphosate, which the WHO s International Agency for Research on Cancer (IARC) now warns may cause NHL and other cancers. Research has existed for years that suggests farm workers and others may face a risk of NHL from glyphosate yet Monsanto has failed to warn those working with the weed killer about the potential risks and about the importance of taking precautions to avoid heavy exposure to Roundup. Symptoms of non-hodgkin s lymphoma from Roundup may include: * Lymph Node Enlargement * Swollen Abdomen * Chest Pain * Difficulty Breathing or Shortness of Breath * Fever, Fatigue, Anemia or Tired Feelings * Sudden Weight Loss Non-Hodgkin s lymphoma attacks the lymphatic system when lymphocytes, white blood cells that are part of the immune system, become cancerous. It can develop in any part of the lymphatic system, such as lymph nodes, the spleen, in bone marrow, or the digestive tract. There are more than 30 various sub-types of non-hodgkin s disease, and the treatment and prognosis for each type of lymphoma may result in different outcomes for individuals exposed to Roundup. 2

Sub-Types of Non-Hodgkin Lymphoma from Roundup Exposure There are two main classifications of NHL that Dunbar Law Office are reviewing cases for: * B-cell Lymphoma * T-cell Lymphoma B-cell Lymphoma Most cases of lymphoma caused by Roundup fall under the B-cell variety, which account for about 85 % of all non-hodgkin s lymphoma diagnosed. The most common sub-type is diffuse large B-cell lymphoma, which comprises about a third of all NHL cases and is considered a high-grade lymphoma or aggressive lymphoma where the cancer may spread quickly and require immediate treatment. Follicular lymphoma from Roundup may be the next most common sub-type which typically makes up about 20% of all cases of the disease. That is followed by marginal zone B-cell lymphomas, which is a subclass that includes extranodal marginal zone B-cell lymphoma, nodal marginal zone B-cell lymphoma and others comprising between 5-10 % of all cases. More rare is mantle cell lymphoma from Roundup, which mostly affects men and sits on the line between being considered aggressive or indolent (low-grade lymphoma) which may grow slower. However, it is treated as an aggressive form. Roundup causing Burkitt lymphoma, lymphaplasmacytic lymphoma and Central nervous system (CNS) lymphoma are also being investigated, but these sub-types rarely 3

comprise more than 2 % each of all cancers considered non-hodgkin lymphoma diagnosed annually. T-Cell Lymphoma T-cell lymphoma cases may also be linked to Roundup, which typically only make up 15% of all NHL cases diagnosed. About half of all T-cell lymphomas are classified as peripheral T-cell lymphoma, which is a term used to indicate an unspecified type that does not fall into any other category. They tend to develop from mature T-cells, often affect the skin and are usually aggressive and longterm survival chances are low. Other subtypes of T-cell lymphoma may include skin lymphoma (also known as cutaneous lymphoma), anaplastic large cell lymphoma and t-cell lymphoblastic lymphoma. Regardless of the type, these cancers are most easily treated when they are localized to one location and many respond well with chemotherapy. However, aggressive lymphomas must be treated fast and thoroughly because the speed at which they spread. Roundup Non-Hodgkins Lymphoma Class Action Lawyers Some research suggests that exposure to the active ingredient in Roundup (glyphosate) may double the overall risk of NHL and triple the risk of B-cell lymphoma. Although many cases of NHL diagnosed among Roundup users may have been avoided if stronger warnings had been provided, it appears that Monsanto placed their desire for profits before consumers safety. Dunbar Law Office, PC is investigating cases nationwide for persons who plan to 4

pursue financial compensation from Monsanto. All cases handled will be on a contingency basis which means that there will be no out-of-pocket costs to hire a lawyer and we receive no attorney s fees or reimbursement of expenses unless a recovery is obtained. Dunbar Law Office, P.C. may share information and/or team with other firms representing plaintiffs in order to better represent those with NHL. Each claim for NHL following exposure to Roundup is subject to a statute of limitations which require that any lawsuit or class action be filed in court within a certain amount of time. Therefore, if you or a loved one were diagnosed with NHL and used Roundup, contact Dunbar Law Office, P.C. today to protect your legal rights. Tom Dunbar, Esq. Dunbar Law Office, P.C. P.O. Box 16369 Jackson, MS 39236 601-366-3170 tomdunbar1@comcast.net 5